View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

argenx Announces Annual General Meeting of Shareholders on May 27, 202...

argenx Announces Annual General Meeting of Shareholders on May 27, 2025 April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 27, 2025 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Annual General Meet...

Thomas Vranken
  • Thomas Vranken

argenx FDA approves Vyvgart Hytrulo as pre-filled syringe for MG and C...

argenx obtained FDA approval for a PFS presentation of Vyvgart Hytrulo for self-injection for patients with AChR+ gMG or CIDP. The 20-30 second injection can now be administered by patients themselves after proper instruction, freeing them to receive treatment in healthcare settings, at home or on the go. With no specific monitoring or training requirements, the label provides a lot of flexibility for patients. We see the approval as the next phase in maintaining Vyvgart's launch momentum as it ...

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Lewi
 PRESS RELEASE

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for...

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringeSelf-injection provides gMG and CIDP patients with flexibility for when and where to receive treatment – at home, while ‘on the go’ or in a healthcare setting Approval reflects commitment to innovating the patient experience with individualized, safe and effective therapies April 10, 2025...

Guy Sips ... (+11)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

US Tariffs Navigating the impact on Benelux equities

Trumps reciprocal tariffs caused a massive blow to equity markets, following a pressured period of escalating trade wars. Retaliatory measures can further heavily damage market confidence, as seen Friday when China announced their 34% tarrif of US goods. International trade policies have never moved this erratic and untransparant, with uncertainty and volatility being the baseline for now. In this report we highlight the key stocks in our coverage relevant to this discussion.

Jacob Mekhael ... (+4)
  • Jacob Mekhael
  • Kristof Samoy
  • Michiel Declercq
  • Thomas Vranken
 PRESS RELEASE

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sus...

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term CIDP data demonstrating VYVGART Hytrulo’s durable efficacy, sustained functional improvements and favorable safety profileargenx continues to advance a robust neuromuscular pipeline of clinical candidates; first-in-human data of ARG...

 PRESS RELEASE

argenx Highlights FcRn Leadership with Long-term Data and Transformati...

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profile of VYVGART and VYVGART HytrulogMG patients on VYVGART achieve rapid, substantial, and sustained efficacy across multiple dosing regimens, supporting individualized treatment approachADHERE+ oral presentation builds upon evidence of VYVGART Hytrulo driving improved functional ability in CIDP Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Eurone...

Aaron Brodjanac ... (+7)
  • Aaron Brodjanac
  • Baptiste Salaville
  • Chaima Ferrandon
  • Charlotte Vaisse
  • Marc Lavaud
  • Sven Edelfelt
  • Thomas Zlowodzki
Aaron Brodjanac ... (+7)
  • Aaron Brodjanac
  • Baptiste Salaville
  • Chaima Ferrandon
  • Charlotte Vaisse
  • Marc Lavaud
  • Sven Edelfelt
  • Thomas Zlowodzki
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Michiel Declercq
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Morning Notes : AALB NA, AGS BB, ARGX BB, CFEB BB, CRBN NA, CMBT BB, M...

: AALB NA, AGS BB, ARGX BB, CFEB BB, CRBN NA, CMBT BB, MDXH BB, PNL NA, UCB BB, VAN BB, WDP BB, CTPNV NA, SYENS BB

Thomas Vranken
  • Thomas Vranken

argenx FIRST LOOK: FY24 results highlight transition to sustainable pr...

argenx reported its FY24 financial results, underscoring Vyvgart's sustained commercial momentum and the company's pivot toward sustainable profitability. Despite increasing competition, we see no signs of stopping. For 2025, we mainly look forward to Vyvgart's ramp-up in CIDP, its PFS approval (PDUFA April 10), a PoC readout in LN and ARGX-119's first clinical results in CMS. We maintain our € 670 TP and Accumulate rating.

 PRESS RELEASE

argenx Reports Full Year 2024 Financial Results and Provides Fourth Qu...

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update $737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for gMG, enabling launch in the EU; FDA PDUFA (gMG and CIDP) on track for April 10 10 Phase 3 and 10 Phase 2 studies across pipeline ongoing in 2025, positioning for next wave of growth Recognized one-time tax benefit of $725 million related to previously unrecognized deferred tax assets Management to host conference call today at 2:30 PM CET...

 PRESS RELEASE

argenx to Present at TD Cowen 45th Annual Healthcare Conference

argenx to Present at TD Cowen 45th Annual Healthcare Conference February 25, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025 at 11:50 a.m. ET. A live webcast of the presentation may be accessed on the Investors section of the argenx website at . A replay of the webcast will be available on the argenx websi...

 PRESS RELEASE

argenx to Report Full Year 2024 Financial Results and Fourth Quarter B...

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025 February 20, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 27, 2025 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2024 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of th...

Argen X SE: 1 director

A director at Argen X SE sold 9,950 shares at 624.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

Bruno Cavalier ... (+2)
  • Bruno Cavalier
  • Stephane Houri
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch